Monthly Archives: October 2002


Documents Show Drug Company Promotion of Unproven Drug_NYT Tue, 29 Oct 2002 Internal company documents unsealed in a federal lawsuit reveal how the unholy alliance between doctors and drug companies has corrupted medical practice and defrauded the US taxpayer. Although it is illegal for drug companies to promote a drug […]

Documents Show Drug Company Promotion of Unproven Drug – NYT



Senate Passes Pediatric Research Equity Act Tue, 29 Jul 2003 Congress and the Bush Administration both are eager to test pharmaceutical products on children who cannot refuse to be test subjects. We at AHRP are in full agreement that medications used in children be thoroughly tested for safety, effectiveness and […]

Senate Passes Pediatric Research Equity Act




AHRP Recommendations for the protection of children in clinical research

(1) Federal regulations are predicated on our moral responsibility to protect children - who are not volunteers - from being subjected to medical or behavioral experiments that are not in their best interest. Thus, federal regulations - 45 CFR 46 Sub-part D - restrict the use of children in medical experiments involving greater than minimal risk, if there is no potential medical benefit for them or their condition.

AHRP Press Release Children Policy Recommendations


Lawsuits & press info RE: SSRI addiction / suicide risk–not scientific literature Fri, 25 Oct To gain knowledge about the scope of a serious threat to public health–i.e., severe adverse drug effects of antidepressant drugs– physicians and consumers must turn to the popular and alternative press, rather than “peer reviewed” […]

Lawsuits & press info RE: SSRI addiction / suicide risk ...



October 11, 2002 Editorial: Trial Lawyers and Clinical Trials_WSJ Daniel Hennenger, the editor of the Wall Street Journal would give doctors free reign to experiment on human subjects unencumbered by ethical or regulatory considerations: just let every self-proclaimed ” genius who somewhere is dreaming of the next L-dopa, lithium or […]

Editorial: Trial Lawyers and Clinical Trials_WSJ